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bjectives This study sought to determine predictors of outcome and examine the inﬂuence of
aseline risk on therapeutic impact of late mechanical opening of a persistently occluded infarct
elated artery after myocardial infarction in stable patients.
ackground Previous studies in patients with acute coronary syndromes suggest that the impact of
nfarct-related artery recanalization on clinical outcome is greatest in patients at highest risk.
ethods Of 2,201 patients (age 58.6  11.0 years) with infarct-related artery occlusion on days 3 to
8 after myocardial infarction in the OAT (Occluded Artery Trial) study, 1,101 were assigned to per-
utaneous coronary intervention (PCI) and 1,100 to medical therapy alone and followed for a mean
f 3.2 years. The primary end point was a composite of death, reinfarction, or New York Heart Asso-
iation functional class IV heart failure. Interaction of treatment effect with tertiles of predicted sur-
ival were examined using the Cox survival model.
esults The 5-year rate for the primary end point was 18.9% versus 16.1% for patients assigned to
CI and medical treatment alone, respectively (hazard ratio [HR]: 1.14, 95% conﬁdence interval [CI]:
.92 to 1.43, p  0.23). Lack of beneﬁt of PCI was consistent across the risk spectrum for both the
rimary end point and total mortality, including for the highest tertile (33.9% PCI vs. 27.3% medical
reatment alone, HR: 1.27, 99% CI: 0.87 to 1.85 primary end point and 23.5% PCI vs. 21.7% medical
reatment alone, HR: 1.16, 99% CI: 0.73 to 1.85 mortality). The independent predictors of the com-
osite outcome were history of heart failure (HR: 2.06, p  0.001), peripheral vascular disease (HR:
.93, p  0.001), diabetes (HR: 1.49, p  0.002), rales (HR: 1.88, p  0.001), decreasing ejection frac-
ion (HR: 1.48 per 10%, p  0.001), decreasing days from myocardial infarction to randomization
HR: 1.04 per day, p  0.001), and decreasing glomerular ﬁltration rate (HR: 1.11 per 10 ml/min/1.73
2, p  0.001).
onclusions In the OAT study, there was no variation in the effect of PCI on clinical outcomes at
ifferent levels of patient risk, including the subset with very high event rates. (Occluded Artery Trial
OAT]; NCT00004562) (J Am Coll Cardiol Intv 2008;1:511–20) © 2008 by the American College of
ardiology Foundation
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512otal occlusion of the infarct-related artery (IRA) may be
etected in up to one-third of all patients surviving the acute
hase of myocardial infarction (MI). Such patients typically
ave not received acute reperfusion therapy due to presen-
ation outside the time window of demonstrated survival
See page 521
enefit, and there are a paucity of data regarding prognostic
actors in this population (1–3). Recently, the OAT (Oc-
luded Artery Trial) study has shown that contemporary
ercutaneous methods used for mechanical recanalization of
RA performed in stable patients with 1- or 2-vessel
oronary disease on days 3 to 28 following MI do not result
n better prognosis when compared with optimal medical
reatment (3). Previous clinical experience with other sub-
ets of acute coronary syndrome (ACS) patients, including
ardiogenic shock after MI, suggests that more aggressive,
nterventional therapies are most beneficial in highest risk
patients (4–7). To test this, we
determined predictors of out-
come in the OAT study and ex-
amined the influence of baseline
risk on the therapeutic impact of
mechanical opening of persistent
IRA and tested the hypothesis
that those at greatest risk may
derive benefit.
Methods
Patient population. The design
and methods of OAT have been
described in detail (3,8). In sum-
mary, 2,201 patients were en-
olled (2,166 between February 2000 and December 2005 in
he main OAT study (3) and 35 patients in the extension
hase of the OAT-NUC (Viability and Remodeling in
AT Ancillary Study) substudy in 2006) and observed for
mean of 3.2 years. Patients who had total occlusion of the
RA on calendar days 3 to 28 (minimum 24 h) after MI
rom the *Institute of Cardiology, Warsaw, Poland; †New York University School of
edicine, New York, New York; ‡Maryland Medical Research Institute, Baltimore,
aryland; §Duke Clinical Research Institute, Durham, North Carolina; Italian
ssociation of Hospital Cardiologist (ANMCO) Research Center, Florence, Italy;
Neufeld Cardiac Research Institute, Tel Hashomer, Israel; #St. Paul’s Hospital,
ancouver, British Columbia, Canada; **Rambam Medical Center, Haifa, Israel;
†Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto-USP, Ribeirao
reto, Brazil; ‡‡Green Lane Cardiovascular Service, Auckland, New Zealand; and the
§University of Miami Miller School of Medicine, Miami, Florida. This study was
upported by National Heart, Lung, and Blood Institute grants to Drs. Hochman
U01 HL062509) and Barton (U01 HL062511). The content is solely the responsi-
ility of the authors and does not necessarily represent the official views of the
ational Heart, Lung, and Blood Institute or the National Institutes of Health.
bbreviations
nd Acronyms
CS  acute coronary
yndrome
F  ejection fraction
RA  infarct-related artery
V  left ventricular
VEF  left ventricular
jection fraction
I  myocardial infarction
YHA  New York Heart
ssociation
CI  percutaneous
oronary interventionpanuscript received July 9, 2008; accepted August 5, 2008.ymptom onset were eligible if they were high risk (i.e.,
jection fraction [EF] 50% or proximal occlusion of the
RA subtending 25% left ventricular [LV] myocardium)
nd remained in stable clinical condition. Major exclusion
riteria included New York Heart Association (NYHA)
unctional class III or IV heart failure, shock, a serum
reatinine concentration 2.5 mg/dl (221 mol/l), angio-
raphically significant left main or 3-vessel coronary artery
isease, angina at rest, and severe ischemia on stress testing
not routinely required but warranted if the infarct zone was
ot akinetic or dyskinetic or multivessel disease was present).
Eligible patients were randomly assigned to percutaneous
oronary intervention (PCI) with stent placement and
ptimal medical therapy (n  1,101) or optimal medical
herapy alone (n  1,100). Per protocol, all patients were to
eceive optimal medical therapy, including aspirin, antico-
gulation if clinically indicated, angiotensin-converting en-
yme inhibition or blockade of angiotensin II receptor,
eta-blockade, and lipid-lowering therapy, unless contrain-
icated. Thienopyridine therapy was to be initiated before
CI and continued for at least 2 to 4 weeks in patients who
nderwent stenting and was recommended for 6 to 12
onths in all patients.
Images from the qualifying angiogram and PCI were
eviewed at the angiography core laboratory. Cardiac mark-
rs (preferably creatine kinase myocardial band or, if not
vailable, troponin I or T or creatine kinase) were to be
easured routinely in both groups 3 times during the first
8 h after randomization and within 24 h after PCI in
atients assigned to PCI.
Institutional review boards at the participating centers
pproved the study protocol, and all patients provided
ritten informed consent. Funding for the present work was
rovided by a grant from the National Heart, Lung, and
lood Institute.
tudy end points. The primary end point of the OAT study
as a composite of death from any cause, reinfarction, or
YHA functional class IV heart failure with hospitalization
r admission in a short-stay unit. This cumulative compos-
te end point and death alone assessed at 5 years comprised
he outcomes of the current analysis.
The study end point events were adjudicated by an
ndependent mortality and morbidity classification commit-
ee, which was unaware of the treatment assignments. The
efinition of reinfarction, which required 2 out of 3 criteria,
as been provided previously (3).
tatistical analysis. Baseline characteristics that had 10%
issing data were used for this analysis (Table 1). Data were
ummarized as frequencies and percentages for categorical
ariables and as the median (with interquartile range) for
ontinuous variables and compared within the risk strata
sing the chi-square test/Fisher exact test or analysis of
ariance, respectively. Univariable and multivariable Cox
roportional hazards models were developed to evaluate the
r
r
N
a
a
b
d
m
a
u
a
v
i
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 5 , 2 0 0 8
O C T O B E R 2 0 0 8 : 5 1 1 – 2 0
Kruk et al.
The OAT Study Risk Factors and Interaction With PCI
513elation between the baseline characteristics and the occur-
ence of the composite of death, myocardial reinfarction, or
YHA functional class IV heart failure during follow-up,
nd, separately, death alone. Factors that were expected to
ffect risk and likely treatment interaction were prespecified
y the OAT protocol (8). However, to determine indepen-
Table 1. Univariable Predictors of Risk of 5-Year Events (Cox Regression)
Com
HR
Clinical characteristics
Age (every 10 yrs) 1.25
Male gender 0.66
White 0.86
History of
Diabetes 2.04
Angina 1.56
MI 1.61
Hypertension 1.57
Cerebrovascular disease 1.88
Peripheral vascular disease* 2.61
Renal insufﬁciency 2.35
Congestive heart failure* 4.42
Percutaneous coronary intervention 2.29
Hypercholesterolemia* 0.94
Family history 0.98
NYHA functional class higher than I during index MI
or prior to randomization*
1.8
Current cigarette smoker 0.95
Heart rate (every 10 beats/min)* 1.27
Systolic blood pressure (every 10 mm Hg decrease)* 1.08
Diastolic blood pressure (every 10 mm Hg decrease)* 1.18
Pulse pressure (every 10 mm Hg decrease)* 1.01
GFR (every 10 ml/min/1.73 m2 decrease)* 1.17
Glucose (every 10 mg/dl)* 1.05
Body mass index (kg/m2)* 1.39
Index event
S3 sounds* 1.76
Highest Killip class 1* 2.16
Rales* 3.17
New Q waves 0.77
ST-segment elevation 1.12
R loss 0.97
ST-segment elevation or new Q waves 0.95
ST-segment elevation or Q waves or R loss 0.99
Thrombolytic in ﬁrst 24 h* 1.06
Time to index MI (every 1-day decrease) 1.03
Angiographic data
Culprit artery LAD 1.34
Any collaterals* 0.68
Multivessel disease* 1.51
LVEF (every 10% decrease)* 1.6ent predictors of outcome, all baseline variables entered the multivariable stage, irrespective of the results of univariable
nalyses. Missing values were imputed as means for contin-
ous variables and, equivalently, medians for binary vari-
bles. Backward elimination was used with p  0.01 for
ariables remaining in the final model. Secondary analysis
ncluded the addition of discharge medications to the
ding to the Presenting Clinical Characteristics
End Point Death
CI p Value HR 99% CI p Value
.43 0.0001 1.41 1.18–1.69 0.0001
.9 0.0007 0.78 0.51–1.2 0.1393
.23 0.2821 0.92 0.58–1.49 0.6697
.78 0.0001 1.86 1.24–2.8 0.0001
.13 0.0003 1.84 1.24–2.75 0.0001
.39 0.0016 1.38 0.82–2.35 0.1133
.11 0.0001 1.7 1.15–2.51 0.0004
.41 0.0063 2.6 1.32–5.09 0.0003
.38 0.0001 2.21 1.1–4.41 0.0033
.63 0.0114 3.06 1.13–8.26 0.0037
.49 0.0001 5.65 3.07–10.4 0.0001
.73 0.0001 2.23 1.17–4.22 0.0013
.26 0.5702 0.84 0.57–1.23 0.2345
.32 0.8587 0.89 0.6–1.33 0.4633
.47 0.0001 2.02 1.35–3.02 0.0001
.28 0.6367 0.7 0.46–1.05 0.0239
.42 0.0001 1.31 1.13–1.52 0.0001
.17 0.0248 1.04 0.94–1.16 0.3035
.34 0.0014 1.05 0.88–1.24 0.4962
.13 0.7505 1.04 0.91–1.2 0.4311
.22 0.0001 1.24 1.12–1.37 0.0001
.08 0.0001 1.01 1.01–1.09 0.0038
.81 0.0015 1.44 1.03–2.02 0.0057
.21 0.0951 2.77 1.15–6.69 0.0029
.96 0.0001 2.72 1.84–4.02 0.0001
.75 0.0001 3.49 2.13–5.73 0.0001
.04 0.0226 0.89 0.6–1.32 0.4537
.54 0.3668 1.27 0.83–1.94 0.1462
.3 0.762 1.23 0.84–1.8 0.1647
.41 0.7574 0.81 0.5–1.3 0.2444
.5 0.9256 0.81 0.49–1.36 0.2917
.51 0.6914 1.1 0.69–1.74 0.6068
.05 0.0002 1.02 0.99–1.05 0.0687
.81 0.0101 1.54 1.06–2.26 0.0033
.02 0.0135 0.74 0.44–1.26 0.1442
.14 0.0024 1.78 1.15–2.74 0.0007
.82 0.0001 1.67 1.42–1.97 0.0001
Continued on next pageAccor
posite
99%
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0.73–1
1.31–2
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1.41–1odels based on the baseline data. The prognostic discrim-
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514natory capacity of the models based on the baseline vari-
bles was measured with the C statistic representing the area
nder the receiver operating characteristic curves for pre-
iction of the composite end point and of death alone.
alibration of the OAT risk multivariable models (i.e., how
losely predicted outcomes agreed with actual outcomes)
as evaluated with Hosmer-Lemeshow chi-square statistics
or goodness of fit.
Prior to the analysis, we prespecified that the patients
ould be divided into tertiles of risk based on the multivariable
ox model predictive of the primary end point. Kaplan-Meier
urves for patients within consecutive risk tertiles were pre-
ented graphically and compared with log-rank tests. Interac-
ion between study assigned treatment and the risk strata was
ssessed with the use of a Cox regression model.
To control for the type I error rate, it was prespecified by
he study protocol that a p value of 0.01 would be
onsidered as showing evidence of differences in secondary
nalyses (8). SAS software version 9.1.3 (SAS Institute,
ary, North Carolina) was used for statistical analyses.
esults
isk predictors. The cumulative 5-year composite primary
Table 1. Continued
Com
HR
Medications
Long-acting nitrate 1.2
Sublingual nitrate 0.94
Beta-blocker 0.84
Calcium channel blocker 1.1
Aspirin 0.93
Ticlopidine 0.87
Clopidogrel 1.2
Ticlopidine or clopidogrel 1.14
Warfarin (coumadin) 1.41
Digoxin 4.42
Diuretic 2.73
Spironolactone 2.46
ACE inhibitor 1.91
ARB 1.22
ACE or ARB 2.21
Insulin 2.46
Oral hypoglycemic 1.74
Lipid-lowering agent 0.76
Antiarrhythmic 2.53
*Missing data: peripheral vascular disease, n 2; congestive heart failure, n 2; hypercholesterolem
n 3; systolic blood pressure, n 2; diastolic blood pressure, n 2; pulse pressure, n 2; GFR, n
4; thrombolytic in first 24 h, n 1; any collaterals, n 28; multivessel disease, n 18; LVEF, n 16
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; CI confidence inte
ventricular ejection fraction; MImyocardial infarction; NYHA New York Heart Association.nd point of death, myocardial reinfarction, or NYHA 1unctional class IV heart failure was 17.5%; the mortality
ate was 11.7%. No significant differences were observed
etween patients assigned to PCI and patients assigned to
ptimal medical therapy alone for the composite outcome
18.9% vs. 16.1%, respectively; hazard ratio [HR]: 1.14,
5% confidence interval [CI]: 0.92 to 1.43, p  0.23) or for
eath (11.7% vs. 11.8%, respectively; HR: 1.00, 99% CI:
.69 to 1.47, p  0.99). The 1-year composite primary end
oint was 9.2%, and death was 4.3%. Univariable analysis of
redictors of the composite outcome and death are listed in
able 1.
ultivariable analysis. The independent predictors of the
rimary composite end point included history of heart
ailure prior to the index MI (HR: 2.06, p  0.001),
eripheral vascular disease (HR: 1.93, p  0.001), diabetes
HR: 1.49, p  0.002), rales at the time of randomization
HR: 1.88, p  0.001), EF (HR: 1.48 per 10% decrease, p
0.001), days from MI to randomization (HR: 1.04 per
ay decrease, p  0.001), and reduced glomerular filtration
ate (HR: 1.11 per 10 ml/min/1.73 m2, p  0.001).
ndependent predictors of death were: Killip class 1
uring index MI (HR: 1.75, p  0.001), history of
erebrovascular disease (HR: 2.28, p 0.002), angina (HR:
End Point Death
CI p Value HR 99% CI p Value
.67 0.1674 1.43 0.94–2.17 0.0267
.29 0.6089 0.79 0.52–1.21 0.1559
.27 0.27 0.84 0.49–1.43 0.396
.95 0.7617 1.19 0.56–2.49 0.56
.83 0.7714 0.74 0.33–1.65 0.3368
.41 0.453 0.9 0.47–1.7 0.6554
.59 0.1368 1.05 0.72–1.53 0.7552
.54 0.2588 1 0.69–1.5 0.9139
.17 0.0397 1.58 0.92–2.7 0.0288
.31 0.0001 4.69 2.58–8.53 0.0001
.73 0.0001 3.2 2.16–4.74 0.0001
.93 0.0001 2.83 1.59–5.03 0.0001
.9 0.0001 1.84 1.08–3.2 0.0034
.6 0.5077 1.14 0.42–3.1 0.7317
.52 0.0001 2.12 1.16–3.82 0.0014
.85 0.0001 2.61 1.48–4.59 0.0001
.5 0.0001 1.65 1.03–2.65 0.0064
.06 0.0341 0.63 0.41–0.96 0.0047
.39 0.0001 3.06 1.62–5.8 0.0001
1; NYHA functional class higher than I during index MI or prior to randomization, n 1; heart rate,
cose, n 200; body mass index, n 16; S3 sounds, n 1; highest Killip class1, n 9; rales, n
site end point death from any cause, nonfatal reinfarction, or NYHA class IV heart failure.
Rglomerular filtration rate; HRhazard ratios; LAD left anterior descending artery; LVEF leftposite
99%
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1.47–4
ia, n
41; glu
. Compo
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515.004), EF (HR: 1.51 per 10% decrease, p  0.001), days
rom MI to randomization (HR: 1.03 per day decrease, p 
.008), and reduced glomerular filtration rate (HR: 1.18,
er 10 ml/min/1.73 m2, p  0.001) (Figs. 1A and 1B,
espectively).
Both multivariable Cox models were modified by addi-
ion of discharge medications. The primary outcome was
urther predicted by digoxin treatment (HR: 2.07, p 
.001) in addition to each of the variables noted in the first
odel except for rales, whereas death was additionally
redicted by insulin prescription at discharge (HR: 1.85, p
0.006) but not by Killip class 1. Multivariable Cox
odels were not modified by the addition of the study
reatment (PCI vs. medical) assignment.
rognostic capacity and calibration of the multivariable Cox
egression models. The areas under the receiver operating
urves for the Cox models in prediction of both the primary
utcome and death showed good discrimination (C statis-
ics 0.720 for the composite end point, and C statistics
.731 for death). The Hosmer-Lemeshow statistics for the
espective OAT multivariable Cox models were not signif-
cant, indicating little departure from a perfect fit (chi-
quare  7.710 and p  0.462) for the composite outcome
nd (chi-square  6.09 and p  0.638) for death.
isk tertiles. Based on the multivariable Cox model for
he primary end point, we divided the study patients into
equal groups based on increasing risk profile. The
umulative 5-year life table event rates for primary end
oint for patients within low-, medium-, and high-risk
ertiles were 8.6%, 13.4%, and 30.6%, respectively. Ac-
ordingly, death occurred in 5.5%, 6.9%, and 22.6% of
ases by tertile.
Baseline characteristics of the 2,201 study patients di-
ided based on risk tertiles is presented in Table 2. Increas-
ng risk tertiles were associated with older age, female
ender, more comorbidities, diabetes, obesity, heart failure
rior to study entry, higher heart rate, lower diastolic blood
ressure, increasing glucose levels, and decreasing glomer-
lar filtration rate. Higher risk patients more often had
T-segment elevation during the index MI, and the time
rom the qualifying event to randomization was substan-
ially shorter than in the lower risk patients. Other features
efining patients with increasing risk tertiles were higher
revalence of the left anterior descending artery as the
ulprit vessel, lower likelihood of collaterals, more extensive
oronary artery disease, and lower EF.
No significant differences were observed between the risk
ubgroups with respect to the periprocedural composite
vent. However, periprocedural death occurred more often
n the highest risk group of patients (n  5) than in the
edium- (n  1) or low-risk (n  0) groups (p  0.01,
isher exact test).
nteraction of treatment effect with the risk strata. The
urvival curves depicting the occurrence of a composite end goint and mortality alone within risk tertiles are provided in
igure 2, and the event rates within consecutive risk tertiles
or the study treatment groups (PCI vs. medical) are
resented in Table 3. There were no statistically significant
ifferences between the 2 treatment groups for any risk
ertile, but in the highest risk patients there was a weak
rend toward more events (composite end point) in the PCI
Hazard Ratio
GFR (10 ml/min decrease)
HR 1.11, 99%CI:1.03-1.20
A
EF (10% decrease)
HR=1.48, 99%CI:1.30-1.68
Days - MI to randomization
HR=1.04, 99%CI:1.01-1.06
History of PVD
HR=1.93, 99%CI:1.14-3.28
History of heart failure
HR=2.06, 99%CI:1.17-3.61
Diabetes
HR=1.49, 99%CI=1.08-2.06
Rales
HR=1 88 99%CI=1 24 2 87
GFR (10 ml/min decrease)
HR=1.18, 99%CI:1.06-1.30
EF (10% decrease)
Hazard RatioB
1.00 10.00
. , . - .
HR=1.51, 99%CI:1.28-1.79
Days - MI to randomization
HR=1.03, 99%CI:1.00-1.06
History of angina
HR=1.57, 99%CI:1.04-2.38
Hi t f CV dis ory o sease
HR=2.28, 99%CI:1.15-4.53
History of heart failure
HR=2.11, 99%CI:1.08-4.13
Killip class>1
HR=1.75, 99%CI:1.15-2.66
1.00 10.00
Figure 1. Independent Baseline Predictors
Independent baseline predictors of (A) 5-year incidence of the primary out-
come (death from any cause, nonfatal reinfarction, or New York Heart Asso-
ciation functional class IV heart failure requiring hospitalization or a stay in
a short-stay unit) and (B) 5-year incidence of death alone. Hazard ratios
(HR) (black squares) and 99% conﬁdence interval (CI) (horizontal lines)
are shown. CV  cerebrovascular; EF  ejection fraction; GFR  glomerular
ﬁltration rate; MI  myocardial infarction; PVD  peripheral vascular
disease,.roup (log-rank p  0.10).
t
e
0
f
D
O
b
w
t
c
o
v
w
a
P
a
o
s
i
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 5 , 2 0 0 8
O C T O B E R 2 0 0 8 : 5 1 1 – 2 0
Kruk et al.
The OAT Study Risk Factors and Interaction With PCI
516There was no significant interaction between the study
reatment and the risk tertile subgroups with respect to
ither the composite end point (interaction p value 
.51) or death (interaction p value  0.17) during
ollow-up.
iscussion
ur study extends the primary findings of the OAT study
y determining clinical variables independently associated
ith long-term adverse prognosis and indicating a consis-
Table 2. Baseline Characteristics According to Tertiles of Risk
All Patients
N  2,201
Assigned to PCI, n (%) 1,101 (50.0) 3
Clinical characteristics
Age, 10 yrs 5.8 (5.0–6.7) 5
Male gender, n (%) 1,717 (78.0) 5
Nonwhite, n (%) 438 (19.9) 1
History, n (%)
Diabetes 454 (20.6)
Angina 495 (22.5) 1
MI 247 (11.2)
Hypertension 1,071 (48.7) 3
Cerebrovascular disease 82 (3.7)
Peripheral vascular disease 83 (3.8)
Renal insufﬁciency 30 (1.4)
Congestive heart failure 52 (2.4)
PCI 105 (4.8)
Hypercholesterolemia 1,142 (51.9) 3
Family history 883 (40.1) 3
Current cigarette smoker, n (%) 859 (39.0) 2
NYHA functional class higher than I during index MI or
prior to randomization, n(%)
459 (20.9) 1
Rales, n (%) 137 (6.2)
Heart rate, 10 beats/min 7.0 (6.3–8.0) 6
Systolic blood pressure, 10 mm Hg 12.0 (11.0–13.0) 12
Diastolic blood pressure, 10 mm Hg 7.0 (6.4–8.0) 7
Pulse pressure, 10 mm Hg 4.8 (4.0–5.6) 5
GFR, 10 ml/min/1.73 m2 7.9 (6.7–9.2) 8
Glucose, 10 mg/dl 11.0 (9.5–12.6) 10
Body mass index, kg/m2 28 (25–31)
Index event
S3 sounds, n (%) 38 (1.7)
Highest Killip class 1, n (%) 417 (19.0)
New Q waves, n (%) 1,475 (67.0) 4
ST-segment elevation, n (%) 1,485 (66.3) 4
R loss, n (%) 913 (41.5) 2
ST-segment elevation or new Q waves, n (%) 1,842 (83.7) 6
ST-segment elevation or Q waves or R loss, n (%) 1,905 (86.6) 6
Thrombolytic in ﬁrst 24 h, n (%) 424 (19.3) 1
Time to index MI, days 8 (5–16)ent lack of benefit of late mechanical recanalization on plinical outcomes irrespective of baseline risk. Importantly,
ur analysis included over 700 patients with a high cardio-
ascular event rate (5-year composite outcome rate of 30.6%
ith death in 22.6%). It has been hypothesized that patients
t higher risk of events would have the most to gain from
CI of the IRA; this is not the case based on the present
nalysis. In fact, we identified a trend toward worse clinical
utcomes including higher PCI procedural risk in the OAT
tudy within the highest risk tertile.
The late open artery hypothesis included several theoret-
cal cardiovascular benefits of late opening of the IRA:
isk
33
Medium Risk
n  734
High Risk
n  734
p
Value*
Group
Differences†
9) 372 (50.7) 363 (49.5) 0.89 none
–6.4) 5.8 (5.0–6.7) 6.1 (5.2–7.0) 0.0001 L  M  H
6) 598 (81.5) 528 (71.9) 0.0001 L, M  H
8) 153 (20.8) 162 (22.1) 0.03 none
) 105 (14.3) 297 (40.5) 0.0001 L  M  H
9) 162 (22.1) 180 (24.5) 0.23 none
) 83 (11.3) 113 (15.4) 0.0001 L  MH
5) 345 (47.0) 422 (57.5) 0.0001 L, M  H
) 19 (2.6) 34 (4.6) 0.11 none
) 15 (2.0) 66 (9.0) 0.0001 L, M  H
) 4 (0.5) 20 (2.7) 0.0004 L, M  H
) 1 (0.1) 51 (6.9) 0.0001 L, M  H
) 32 (4.4) 52 (7.1) 0.001 L  H
9) 380 (51.8) 367 (50.0) 0.33 none
3) 308 (42.0) 272 (37.1) 0.11 none
8) 317 (43.2) 250 (34.1) 0.001 M  H
2) 122 (16.6) 233 (31.7) 0.0001 L, M  H
) 13 (1.8) 122 (16.6) 0.0001 L, M  H
–7.5) 7.0 (6.3–7.8) 7.5 (6.7–8.4) 0.0001 L  M  H
0–13.0) 12.0 (11.0–13.0) 12.0 (10.5–13.0) 0.01 L  H
–8.0) 7.0 (6.3–8.0) 7.0 (6.2–8.0) 0.0001 L  H
–5.5) 4.9 (4.0–5.5) 4.8 (4.0–5.8) 0.83 NS
–10.1) 7.9 (6.7–9.1) 7.2 (5.9–8.4) 0.0001 L  M  H
–12.0) 11.0 (9.5–12.3) 12.0 (10.3–14.6) 0.0001 L  M  H
30) 28 (26–31) 28 (25–32) 0.0001 L  M, H
) 9 (1.2) 27 (3.7) 0.0001 L, M  H
1) 104 (14.2) 232 (31.6) 0.0001 L, M  H
8) 498 (67.8) 487 (66.3) 0.82 none
8) 481 (65.5) 551 (75.1) 0.0001 L, M  H
8) 297 (40.5) 324 (44.1) 0.19 none
9) 605 (82.4) 629 (85.7) 0.19 none
8) 629 (85.7) 647 (88.1) 0.30 none
1) 137 (18.7) 154 (21.0) 0.34 none
3) 8.0 (4–13) 6 (4.0–11.0) 0.0001 L  M  H
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517ion by recovery of hibernating myocardium, increased
lectrical stability, or capacity of a patent IRA to provide
ollaterals in the event of future remote occlusion. Despite
3% patency rate for intervened IRA after 1 year and an
pparent positive impact of IRA recanalization on LV
emodeling reported in the TOSCA (Total Occlusion
tudy of Canada)-2 trial, the results of the OAT study have
hown that these potential benefits do not translate into
ower rates of heart failure, death, and reinfarction during 5
ears of follow up.
isk determinants. According to our data, the 5-year prog-
osis of the OAT study patients seemed to be determined
rimarily by comorbidities, and the cardiac component was
epresented only modestly by left ventricular ejection frac-
ion (LVEF) or heart failure. In the angiographic OAT
ubstudy, TOSCA-2, PCI of the IRA had no influence on
VEF (9) at 1 year. Lack of influence of IRA recanalization
n LVEF may partially explain the lack of interaction
etween the risk strata and the study treatment observed in
he current analysis. Alternatively, the potential effect of EF
Table 2. Continued
All Patients
N  2,201
Low Risk
n  733
Angiographic data
Culprit artery LAD, n (%) 793 (36.0) 178 (24.3)
Any collaterals, n (%) 1,950 (88.4) 677 (92.4)
Multivessel disease, n (%) 379 (17.2) 103 (14.1)
LVEF, per 10% 4.8 (4.0–5.5) 5.6 (5.1–6.1)
Medications, n (%)
Long-acting nitrate 498 (22.6) 162 (22.1)
Sublingual nitrate 652 (29.6) 210 (28.6)
Beta-blocker 1,932 (87.8) 648 (88.4)
Calcium channel blocker 129 (5.9) 51 (7.0)
Aspirin 2,105 (95.6) 715 (97.5)
Ticlopidine 259 (11.8) 106 (14.5)
Clopidogrel 1,075 (48.8) 338 (46.1)
Warfarin (coumadin) 215 (9.8) 32 (4.4)
Digoxin 61 (2.8) 1 (0.1)
Diuretic 371 (16.9) 55 (7.5)
Spironolactone 124 (5.6) 20 (2.7)
ACE inhibitor 1,714 (77.9) 534 (72.9)
ARB 70 (3.2) 18 (2.5)
Insulin 137 (6.2) 17 (2.3)
Oral hypoglycemic 298 (13.5) 39 (5.3)
Lipid-lowering agent 1,788 (81.2) 627 (85.5)
Antiarrhythmic 84 (3.8) 14 (1.9)
Ticlopidine or clopidogrel 1,329 (60.4) 443 (60.4)
ACE or ARB 1,771 (80.5) 549 (74.9)
Values are presented as frequencies (percentages) for categorical variables and as the median (inte
difference between the 3 groups. †The group differences are based on Duncan’s multiple range t
differences are presented for p 0.01.
L low, Mmedium, H high; PCI percutaneous coronary intervention; other abbreviationsay have been moderated by use of optimal medical pherapy, which is particularly effective for risk reduction
mong patients with low LVEF.
The OAT study population was composed primarily of
atients with 1- or 2-vessel disease, and the comorbid
onditions identified as predictors of outcome are likely to
ct at least in part via acceleration of coronary artery disease
rogression. Predictors of outcome in the OAT study are
argely concordant with predictors of outcome in prior
tudies of stable coronary disease and ACS patients. The
isk in ACS is largely determined by pump function, which
s typically reflected by heart rate, blood pressure, or Killip
lass at presentation (10–15). The LVEF consistently
orrelated to risk of events, particularly death and heart
ailure, in both acute and chronic coronary artery disease
11,14,15). Renal dysfunction and diabetes have each been
hown to be strong risk determinants of cardiovascular
vents in multiple previous studies as well as in our results
16–18). Peripheral vascular and cerebrovascular diseases
onstitute important cardiovascular risk determinants in
atients with and without established coronary disease
Medium Risk
n  734
High Risk
n  734
p
Value*
Group
Differences†
222 (30.2) 393 (53.5) 0.0001 L, M  H
658 (89.6) 615 (83.8) 0.0001 L, M  H
113 (15.4) 163 (22.2) 0.0001 L, M  H
4.9 (4.5–5.3) 4 (3.2–4.6) 0.0001 L  M  H
173 (23.6) 163 (22.2) 0.76 none
220 (30.0) 222 (30.2) 0.77 none
637 (86.8) 647 (88.1) 0.60 none
37 (5.0) 41 (5.6) 0.27 none
699 (95.2) 691 (94.1) 0.005 L  H
90 (12.3) 63 (8.6) 0.002 L  H
367 (50.0) 370 (50.4) 0.79 none
51 (6.9) 132 (18.0) 0.0001 L, M  H
12 (1.6) 48 (6.5) 0.0001 L, M  H
88 (12.0) 228 (31.1) 0.0001 L, M  H
36 (4.9) 68 (9.3) 0.0001 L, M  H
560 (76.3) 620 (84.5) 0.0001 L, M  H
20 (2.7) 32 (4.4) 0.08 none
28 (3.8) 92 (12.5) 0.0001 L, M  H
79 (10.8) 180 (24.5) 0.0001 L M  H
601 (81.9) 560 (76.3) 0.0001 L, M  H
18 (2.5) 52 (7.1) 0.0001 L, M  H
454 (61.9) 432 (58.9) 0.5 none
576 (78.5) 646 (88.0) 0.0001 L, M  H
range) for continuous variables. *The p values were determined using analysis of variance for any
ch controls the type I comparisonwise error rate, not the experimentwise error rate. The group
able 1.rquartile
est, whiossibly related to more severe coronary atherosclerosis
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51819–23). The impact of peripheral vascular disease, nearly
oubling the risk of the composite event observed in our
tudy, was comparable to previously reported data regarding
atients undergoing PCI (20). Additionally, history of
troke may be a common denominator of patients with atrial
brillation or more advanced heart failure (19,23).
The addition of discharge medications to the multivari-
ble Cox models showed that digoxin use was indepen-
ently associated with the composite outcome and that
nsulin treatment was associated with death during follow-
A
B
C -
-
-
Figure 2. Kaplan-Meier Survival Curves
Kaplan-Meier survival curves for Cox model low-risk (A), medium-risk (B), and
reinfarction, or New York Heart Association functional class IV heart failure req
patients randomized to medical treatment (MED) are represented by dashed l
(PCI) treatment are represented by solid lines. CHF  congestive heart failurep. These results likely reflect the association between use of these medications and the presence of more advanced heart
ailure or unaccounted comorbidities such as atrial fibrilla-
ion in the case of digoxin. Similarly, insulin treatment may be
marker of a more advanced stage or longer duration of
iabetes (16,18). However, we cannot exclude causal relations.
he lack of an apparent protective effect of angiotensin-
onverting enzyme or angiotensin-receptor blocker or beta-
locker is likely due to limited power related to the fact that
ost patients received these medications.
Increasing patient age was observed for higher risk
isk (C) tertiles for the composite outcome (death from any cause, nonfatal
hospitalization or admission to a short-stay unit) or death. The group of
he group of patients randomized to percutaneous coronary intervention
r abbreviations as in Figure 1.high-r
uiring
ines; tertiles. However, unlike many other studies, in our analysis,
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519ge did not emerge as an independent risk predictor. This
as also shown in a study of untreated post-MI patients
24), in which patient age was associated with in-hospital
ortality but did not predict death after discharge. The
djustment for estimated creatinine clearance, which in-
ludes age, may have influenced this finding.
isk proﬁle of the OAT cohort. One-year mortality in OAT
as 4.3%, and the composite of death, heart failure, or
nfarction occurred in 9.2% of cases. These rates appear to
e substantially higher than 1-year event rates reported
reviously for stable angina patients in the Euro Heart
urvey (mortality 1.5%, composite event rate 3.8%) and
ore similar to 6-month mortality in ACS patients in the
RACE (Global Registry of Acute Coronary Events)
egistry (4.8%) or in acute ST-segment elevation MI pa-
ients treated invasively (4.0%) (14,25). Thus, despite being
elatively stable for a post-MI cohort, OAT patients overall
ere at characteristically high risk, comparable to that of
cute ACS treated in a timely manner. In addition, the
hape of the event curves, marked by a steep rise in the early
eriod and stabilization at a lower, constant rate thereafter,
re more comparable to ACS than to stable angina. The
nding of a strong relationship between the number of days
ince the qualifying MI to study entry and the risk of events
n the current study highlights the timing of highest risk
ery early after MI.
ack of PCI beneﬁt across the risk strata: clinical implica-
ions. The subset (over 700 patients) with the highest risk
f cardiovascular events had a high prevalence of the left
nterior descending artery as the culprit artery, diabetes,
igns of heart failure during or after the index MI, or
elatively low LVEF. The lack of interaction between risk
ertile and treatment effect suggests that none of the large
umber of characteristics studied can identify patients who
ould benefit from PCI of the persistently occluded IRA in
table patients with 1- to 2-vessel disease. As noted in the
riginal OAT report, predefined subgroup variables of
Table 3. Life Table 5-Year Event Rates (%) Across the Risk Tertiles
in PCI and Medical Groups
Composite End Point Death
Risk
Tertile
Treatment
p
Value
Treatment
p
ValuePCI Medical PCI Medical
Low 10.2 7.3 0.57 3.8 6.8 0.64
Medium 13.1 13.8 0.82 6.8 7.1 0.26
High 33.9 27.3 0.10 23.5 21.7 0.41
Log-rank test used for comparison of survival within the risk strata. Interaction between the study
treatment and the risk tertile subgroups with respect to death (p 0.17) and the composite end
point (p  0.51). Composite end point  death from any cause, nonfatal reinfarction, or NYHA
functional class IV heart failure.
Abbreviations as in Tables 1 and 2.nterest, including time from index MI, culprit vessel,aseline EF, diabetes, heart failure, and severity of coronary
isease did not interact individually with treatment (3).
hese findings also suggest that enrollment of more patients
ith low EF or heart failure, or closer to 24 h after MI
ould not have altered the findings of the OAT study.
ased on the current analysis, routine interventional treat-
ent of the occluded IRA in stable patients without
ignificant spontaneous or inducible ischemia days to weeks
fter MI should be discouraged.
tudy limitations. The main limitations of our study are
hose inherent to the subgroup analyses, which included
ultiplicity, smaller size, and confounding. To compensate
or these limitations, we applied statistical models with
areful control for type I error rate, which should have
imited the chance of finding false predictors. However, due
o application of our statistical methods, we may have
issed some predictors that are clinically significant.
Importantly, these results are only applicable to patients
ho would have qualified for inclusion in the OAT study.
he results do not apply to post-MI patients with severe
eart failure, electrical instability, angina at rest, severe
nducible ischemia, or 3-vessel disease.
onclusions
he occurrence of adverse events in patients with persistent
otal IRA occlusion after MI who are clinically stable is
ssociated with easily identifiable clinical variables, which
ay guide further medical management. Late recanalization
f the IRA does not reduce the rate of clinical events after
I regardless of baseline risk and may be associated with
ncreased risk in the highest risk patients.
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